Company intelligence / Profile preview

DiaMed Holding

Cressier, Neuchâtel, Switzerland

Ownership: Private
Employees: ~800
Development stage: Other

Overview

DiaMed Holding AG was a Swiss-based medical diagnostics company that specialized in the field of immunohematology. The company is globally recognized for developing the ID-System, a revolutionary gel-based technology used for blood grouping, phenotyping, and antibody screening. This technology standardized blood testing procedures, significantly improving safety and efficiency in blood banks and clinical laboratories. In 2007, DiaMed was acquired by Bio-Rad Laboratories, which integrated DiaMed's extensive portfolio of reagents and automated systems into its clinical diagnostics division. Today, the legacy of DiaMed continues as a core component of Bio-Rad's transfusion medicine business.

Therapeutic areas: Hematology
Modalities: DeviceIn vitro diagnostics
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on DiaMed Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DiaMed Holding.

Explore the full profile